KalVista Pharmaceuticals, Inc. (KALV) Financials

KALV Assets vs Liabilities
DateAssetsLiabilities
April 30, 2026 335.4 million 338.1 million
Jan. 31, 2026 335.4 million 338.1 million
Oct. 31, 2025 339.9 million 322.9 million
July 31, 2025 215.5 million 174.7 million

KALV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
April 30, 2026 45.5 million ?
Jan. 31, 2026 -14.6 million 5.1 million
Oct. 31, 2025 -14.6 million -11.6 million
July 31, 2025 -54.8 million 5.4 million

KALV Net Income

No data available :(

KALV Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
April 30, 2026 300.2 million 258.3 million 10.7 million
Jan. 31, 2026 300.2 million 139.2 million 12.3 million
Oct. 31, 2025 309.2 million 139.0 million 10.6 million
July 31, 2025 191.5 million - 6.1 million

KALV Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
April 30, 2026 50.5 million
Jan. 31, 2026 51.2 million
Oct. 31, 2025 50.9 million
July 31, 2025 53.5 million

KALV Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
April 30, 2026 156000 8.8 million 58.6 million -
Jan. 31, 2026 121000 12.4 million 48.4 million -
Oct. 31, 2025 121000 12.0 million 46.5 million -
July 31, 2025 290000 15.2 million 44.7 million -

KALV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
April 30, 2026 59.9 million 4.0 million
Jan. 31, 2026 40.9 million 3.4 million
Oct. 31, 2025 13.7 million 1.2 million
July 31, 2025 1.4 million 590000

KALV

Price: $27

52 week price:
9.83
27.00

Earnings Per Share: -3.94 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 731100

Ebitda: -22.6 million

Market Capitalization: 1.4 billion

Links: